Webinar Date:

• Beijing Time: 16:00-17:30 pm, Sunday, December 11, 2022
• Tokyo Time: 17:00-18:30 pm, Sunday, December 11, 2022
• Central European Time (Belgium, Netherlands): 09:00-10:30 am, Sunday, December 11, 2022
• US PST Time: 12:00-1:30 am, Sunday, December 11, 2022

Language:

• English, with Chinese Simultaneous Translation

Venue:

• Live Zoom Webinar

Webinar Agenda

► Session #1 Moderator：

• Dr. Feng Wang, Sun Yat-sen University Cancer Center

► Opening Remarks:

• China Co-Chair: Dr. Ruihua Xu, Sun Yat-sen University Cancer Center
• Global Co-Chair: Dr. Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven

► Session #2 Moderator：

• Dr. Ruihua Xu, Sun Yat-sen University Cancer Center

► INITIATE: "Reflect" and "Explore" Induced by JUPITER-06

• Dr. Feng Wang, Sun Yat-sen University Cancer Center

► REFLECT: Meta-Analysis: Efficacy Evaluation of PD-1 Antibody Combined with Chemotherapy on Advanced Esophageal Squamous Cell Carcinoma and Low PD-L1 Expression

• Dr. Haoxiang Wu, Sun Yat-sen University Cancer Center

► 16:35-16:50 Expert Perspectives：

• Dr. Ken Kato, National Cancer Center Hospital, Tokyo
• Dr. Zhihua Liu, Cancer Hospital Chinese Academy of Medical Sciences
• Dr. Qin Lin, The First Affiliated Hospital of Xiamen University

► Session #3 Moderator：

• Dr. Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven

► EXPLORE: Chemo-Immunotherapy in Advanced ESCC: Present and Future

• Dr. Zixian Wang, Sun Yat-sen University Cancer Center

► Expert perspectives:

• Dr. Bas Wijnhoven, ErasmusUniversity Medical Center
• Dr. Guihua Wang, Tongji Hospital, Tongji Medical College of HUST
• Dr. Feng Wang, The First Affiliated Hospital of Zhengzhou
• Dr. Jianzhong Cao, Shanxi Provincial Cancer Hospital

►Session #4 Conference Summary:

• China Co-Chair: Dr. Ruihua Xu, Sun Yat-sen University Cancer Center
• Global Co-Chair: Dr. Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven

Speakers and Panelists Bio

Dr. Eric Van Cutsem, University Hospitals Gasthuisberg / Leuven & KULeuven

Eric Van Cutsem, MD, PhD, is full professor and Division Head of Digestive Oncology at University Hospitals Gasthuisberg & KULeuven, Belgium.

He is a member of the Belgian Royal Academy of Medicine and president of the Belgian Foundation against Cancer (Stichting tegen Kanker; Fondation contre le Cancer). In 2018 he became doctor honoris causa of the Medical University of Warsaw, Poland and received several national and international awards, amongst which were in 2019 the ESMO Award and the European Awards in Medicine for Cancer Research.

He published extensively: >670 articles in PubMed and more than 1500 according Thomson Web of Science, leading to more than 100.000 citations and an H-factor of 140. His research interests are various aspects of Gastrointestinal and Digestive cancers (colorectal, gastric, pancreas, bile duct, esophageal cancer and neuroendocrine tumors).

He co-founded and is chair of ESMO GI/World Congress on Gastrointestinal Cancer in Barcelona, Spain. He serves/served on the board or key committee of ESMO (European Society Medical Oncology; executive board, several committees), UEG (United European Gastroenterology; educational committee, public affairs committee, scientific committee), ASCO (American Society of Clinical Oncology; program committee, international affairs committee), ENET (European NeuroEndocrine Society; advisory board), EORTC (European Organisation Research Treatment Cancer; executive board, chair of GI Cancer group), ECO (European Cancer Organisation; program committee), ESDO (European Society Digestive Oncology; president), ESO (European School of Oncology; Scientific council) and of patient advocacy groups EuropaColon (medical director) and Digestive Cancers Europe (DICE; co-founder, executive board) and the Foundation Engie (CSR) France & Belgium.

He was chairman of the governmental colon cancer prevention task force in Flanders, Belgium, was/is in Belgian active as president and treasurer of Belgian Group Digestive Oncology and as president/vice-president of Familial Polyposis Association (FAPA).

He is/was member of the Scientific Advisory board for different international hospitals/cancer centers: INCA, Paris, Toulouse & Paris, France; University of Ulm & Leipzig, Germany; Humanitas Hospital, Milan & Avignon, France and is member of the board of directors of the regional hospital of Halle, Belgium.

He is member of the governmental commission of recognition for specialists in gastroenterology/ digestive oncology.

Dr. Ruihua Xu, Sun Yat-sen University Cancer Center

Professor of Medical Oncology, President of Sun Yat-sen University Cancer Center, Director of State Key Laboratory of Oncology in South China, President of Chinese Society of Clinical Oncology (CSCO), Vice president of China Anti-cancer Association (CACA), Editor-in-Chief of Cancer Communications (IF 15.3)

Prof. Rui-hua Xu has been deeply engaged in the clinical work of medical oncology, and has made internationally advanced and innovative achievements in digestive system tumors, including early diagnosis, treatment and metastatic drug resistance:

1. He has pioneered a variety of treatment programs for advanced gastrointestinal tumors in the world. A new system for the whole course of colorectal cancer treatment has been developed, and the targeted therapy strategy for advanced gastric cancer under the guidance of molecular markers has been optimized. Many research results have been cited by the NCCN guidelines and have become a new international standard.

2. The application of ctDNA methylation technology and artificial intelligence-assisted endoscopy technology has improved the early diagnosis rate of digestive system tumors.

3. Breakthroughs have been made in the study of drug resistance in tumor metastasis, and the immunotherapy strategy guided by molecular markers has been innovated, which has significantly improved the efficacy and promoted the development of new drug clinical research in China.

The results from his research have been recorded into many international guidelines and classic monographs, which are popularized and applied all over the world. He has been selected as a highly cited scholar in China. Also, he is the editor-in-chief of the national postgraduate textbook "Oncology". Published 200 high-level papers as a correspondent or first author, and many articles were published in important international academic journals, such as "JAMA", "Nature Materials", "Nature Medicine", "Lancet Oncology", "Journal of Clinical Oncology", "JAMA Oncology", “Cancer Cell” etc.

Dr. Bas Wijnhoven, Erasmus University Medical Center

Bas Wijnhoven went to medical school in Utrecht the Netherlands. After obtaining his MD, he started a PhD program on molecular and clinical aspects of oesophageal cancer at the Erasmus MC in Rotterdam. In 2001 he received his PhD with honor. In the year 2006 he was registered as general surgeon.

From 2006 till 2008 he worked as a researcher and surgeon at the Department of Surgery, Flinders Medical Center, Adelaide, Australia. Within these two years he enjoyed a fellowship in upper gastrointestinal and hepatobiliairy surgery.

Since 2008 he is appointed as staff surgeon at the Erasmus MC Rotterdam and is program leader on oesophageal and gastric diseases. His clinical interests are benign and malignant diseases of the upper gastrointestinal tract. Research is focused on studies on clinical outcome after surgery for gastric and oesophageal cancer and the molecular biology of Barrett’s oesophagus and adenocarcinoma. In close collaboration with other departments within the Erasmus MC, preclinical and clinical studies on neoadjuvant treatment for oesophageal and gastric cardia cancer are another area of great interest.

Dr. Wijnhoven is interested in medical publishing and since 2014 he is full-editor for BJS (British Journal of Surgery). He has authored and co-authored over 250 articles in national and international peer-reviewed journals.

Dr. Ken Kato, National Cancer Center Hospital, Tokyo

Chief, Department of Head and Neck, Esophageal Medical OncologyChief, Department of Gastrointestinal Medical OncologyChief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support OfficeNational Cancer Center Hospital, Tokyo, Japan

RESEARCH INTEREST

Chemotherapy and chemoradiotherapy for upper-GI tumorMultimodal treatment for esophageal cancerBiobank and translational research

PROFESSIONAL EXPERIENCES

2004-2006 Chief Resident, National Cancer Center Hospital, Tokyo2006-2012 Medical staff, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo2013-Present Chief, Biobank Translational Research Support Section, Clinical Research Coordinating Section, Clinical Research Support Office2020-Present Chief, Department of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo2021-Present Chief, Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo

PUBLICATIONS

2019 Kato K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Sep 27.: S1470-2045(19)30626-6.

2021 Sun JM, Kato K, et al. Pembrolizumab plus chemotherapy versus chemotherapy for first-line, advanced esophageal cancer: the randomized, placebo-controlled phase 3 KEYNOTE-590 study Lancet in press 2021

2021 Kato K, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma Gastroenterology in press 2021

Dr. Feng Wang, Sun Yat-sen University Cancer Center

PhD. , MD Anderson Cancer CenterCommittee Member, Chinese Society of Clinical OncologyCommittee Member, Youth Expert Committee of China Anti Cancer AssociationVice Director, Youth Expert Committee of the Professional Committee of Targeted Therapy of Tumor, Chinese Anti-Cancer AssociationDirector, Youth Expert Committee of the Professional Committee of Targeted Therapy, Guangdong Province Anti-Cancer AssociationCommittee Member, Committee of Colon Cancer, Chinese society of clinical oncology

Dr. Haoxiang Wu, Sun Yat-sen University Cancer Center

Resident & Secretary of Education in Phase I Clinical Trial Ward, Sun Yat-sen University Cancer Center Major in Medical Oncology & Translational Research in Gastrointestinal Cancer Grant from National Natural Science Foundation of China & the China Postdoctoral Science Foundation Publication on Journal of Clinical Oncology、Gut、Journal of Hematology & Oncology、 Journal for Immunotherapy of Cancer as First(co-first) Author

Dr. Zixian Wang, Sun Yat-sen University Cancer Center

Associate Chief Physician, Department of Medical Oncology, Sun Yat-sen University Cancer Center Chief Scientist, Laboratory of Artificial Intelligence & Data Science, Sun Yat-sen University Cancer Center Standing Committee Member, Clinical Trial Standardization Committee of Guangdong Medical Device Association Council Member, Guangzhou Anticancer Association Co-editing 《China’s e-Science Blue Book 2018》 Funded by National Natural Science Foundation of China, National Key R&D Program Publications in Cancer Cell, Gut, Lancet Oncol, JAMA Oncol, Ann Oncol, JNCCN, Genome Med, CCR, etc.; h-index 18

Dr. Zhihua Liu, Cancer Hospital Chinese Academy of Medical Sciences

Dr. Liu obtained her Ph.D. in Biology from Peking University (1993) and did post-doctoral studies in Washington State University. She joined the State Key Lab of Molecular Oncology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences since 1997, and currently she is a professor and director of the State Key Lab, and the vice present of the hospital.

Dr. Liu’s research focuses on the molecular mechanism of esophageal cancer development and metastasis as well as the translational study. During the past years, her laboratory has identified some transcription factors, E3 ubiquitin ligases and DUBs involved in cancer metastasis, established animal models for esophageal tumorigenesis and metastasis.

The long term goal is to understand the role of these genes in esophageal squamous cell carcinoma and to develop new intervention strategies based on the understanding of cancer development, find biomarkers for early detection, and build the clinically-relevant molecular classification and further improve the understanding and treatment of esophageal squamous cell carcinoma.

Dr. Qin Lin, The First Affiliated Hospital of Xiamen University

The First Affiliated Hospital of Xiamen UniversityXiamen Cancer CenterVisiting Scholar, M. D. Anderson Cancer Center & DUKE UniversityMember of Radiation Oncology Therapeutics Branch, Chinese Medical AssociationHead and Neck Group leader of Radiation Oncology Branch of Chinese Medical Doctor AssociationMember of Radiation Oncology Branch, Chinese Anti-Cancer AssociationVice President of Fujian Anti-cancer AssociationChairman of Oncology Branch, Xiamen Medical AssociationDirector of Xiamen Cancer Quality Control Center

Dr. Guihua Wang, Tongji Hospital, Tongji Medical College of HUST

Deputy Director of Department of General Surgery, Tongji Hospital, Tongji Medical College of HUST

Distinguished Professor of Huazhong University of Science and Technology;

National Youqing 2019, Head of Innovative Group of Hubei Province, Chutian Scholar, Huazhong Excellent Scholar;

National Natural Science Foundation of China (2022);

Standing Committee Member of Professional Committee of Peritoneal Neoplasm, Chinese Anti-Cancer Association;

Member of Professional Committee of Oncologic Gastroenterology, Chinese Anti-Cancer Association;

Member of Translational Medicine Group, Anorectal Physician Branch, Chinese Medical Doctor Association;

Director of Council of Hubei Medical Doctor Association;

Vice Chairman of Youth Committee of Wuhan Medical Association General Surgery Branch;

He has undertaken 6 national key R & D plans and National Natural Science Foundation of China, published more than 20 research treatises in Cell "," Nature Cell Biology "," Journal of Clinical Investigation "," Nature Communications " and other journals, and obtained 1 national clinical approval document for Class I new drugs as a co-developer.

Dr. Feng Wang, The First Affiliated Hospital of Zhengzhou

Chief physician, Professor, Doctoral supervisor, Director, Department of Oncology, The First Affiliated

Hospital of Zhengzhou

Leading talents of Health Science and Technology in Henan Province

Young and middle-aged academic leader of Henan Province

Visiting Scholar of Georgetown University, USA

Deputy editor of the Journal of Esophageal Diseases

2020 “Good Doctor of the People. Jinshan Camellia Project” Outstanding Contribution Award

(Esophageal Cancer Field)

Director, Chinese Society for Diseases of the Esophagus (CSDE)

Director, Chinese Society of Clinical Oncology (CSCO)

Member, Esophageal and Gastric Cancer Committee, Chinese Society of Clinical Oncology (CSCO)

Member, Liver Cancer and Pancreatic Cancer Committee, Chinese Society of Clinical Oncology

(CSCO)

Member, Esophageal Cancer Quality Control Expert Committee, National Cancer Center

Member, Esophageal Cancer, Sarcoma and International Medical Exchange Committee, Chinese

anti-Cancer Association

Vice Chair and member, Standing Committee of Esophageal Cancer and Gastric Cancer Special

Committee, Beijing Cancer Prevention and Control Association

Chairman, Esophageal Cancer Group, Cancer Branch, Henan Medical Association

Standing Committee member, Cancer Branch, Henan Medical Association

Director, Henan anti-Cancer Association

Chairman, Sarcoma Special Committee, Henan anti-Cancer Association

Deputy Chairman, Chairman of the Youth Committee, Oncology Drug Clinical Research Committee,

Henan anti-Cancer Association

Deputy Chairman, Chairman of the Youth Committee, Esophageal Cancer Committee, Henan anti?Cancer Association

Deputy Chairman, Pancreatic Cancer Special Committee, Henan anti-Cancer Association

Director, Henan Provincial Key Laboratory of Translational Research of Upper Gastrointestinal Cancer

Director, Henan International Joint Laboratory for Immunoresistance and Translational Research of

Gastrointestinal Cancer

Dr. Jianzhong Cao, Shanxi Provincial Cancer Hospital

Deputy chairman of radiotherapy branch of Chinese Geriatric Oncology Committee Deputy chairman of radiotherapy Committee of China Education Association Young member of radiotherapy Committee of Chinese Medical Association Member of radiotherapy Committee of Chinses Anti Cancer Association Member of lung cancer group of radiotherapy Committee of Chinese Medical Association

Organizers: